Skip to Content


Treatment for Multiple Myeloma

Update: Kyprolis (carfilzomib) Now FDA Approved - July 20, 2012

Onyx Pharmaceuticals to Hold Conference Call on June 20, 2012 to Discuss FDA Advisory Committee Recommendation for Kyprolis

SOUTH SAN FRANCISCO, Calif., June 19, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. today announced that its management team will host a webcast and conference call on June 20, 2012 at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time) to discuss the outcome of the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee's (ODAC) recommendation under the accelerated approval pathway regarding Kyprolis (proposed brand name for carfilzomib).  Onyx is seeking accelerated approval for Kyprolis for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including a proteasome inhibitor and an immunomodulatory agent (IMiD).

To access a live audio webcast of the conference call, log onto the company's website at:

To access the live conference call on June 20, 2012, dial (847) 585-4405 and use the passcode 32594605. A replay of the call will be available on the Onyx website or by dialing (630) 652-3042 and using the passcode 3259 4605# approximately two hours after the conference call concludes through July 4, 2012.

About Onyx Pharmaceuticals, Inc.

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer.  The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at

SOURCE Onyx Pharmaceuticals, Inc.

CONTACT: Amy Figueroa, +1-650-266-2398

Web Site:


Posted: June 2012

Related Articles

Kyprolis (carfilzomib) FDA Approval History